½ÃÀ庸°í¼­
»óǰÄÚµå
1264101

¼¼°èÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå : ±âȸ¿Í Àü·«(-2032³â)

BiSpecific mAbS Global Market Opportunities And Strategies To 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Business Research Company | ÆäÀÌÁö Á¤º¸: ¿µ¹® 275 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÀÌ º¸°í¼­´Â Àü·« ´ã´çÀÚ, ¸¶ÄÉÆÃ ´ã´çÀÚ, °æ¿µÁøÀÌ COVID-19 ºÀ¼â¿¡¼­ ¹þ¾î³­ ¼¼°èÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀåÀ» Æò°¡ÇÏ´Â µ¥ ÇÊ¿äÇÑ Áß¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×üÀÇ °¡Àå Å©°í °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â ½ÃÀåÀº ¾îµðÀΰ¡? ±× ½ÃÀåÀº Àüü °æÁ¦, Àα¸µ¿ÅÂ, ´Ù¸¥ À¯»çÇÑ ½ÃÀå°ú ¾î¶»°Ô °ü·ÃµÇ¾î Àִ°¡? ¾ÕÀ¸·Î ¾î¶² ÈûÀÌ ½ÃÀåÀ» Çü¼ºÇØ ³ª°¥ °ÍÀΰ¡? ÀÌ º¸°í¼­´Â ÀÌ·¯ÇÑ ¸ðµç Áú¹®°ú ´Ù¸¥ ¸¹Àº Áú¹®¿¡ ´ëÇÑ ´äº¯ÀÌ µÉ °ÍÀÔ´Ï´Ù.

º» º¸°í¼­¿¡¼­´Â ½ÃÀå Æ¯Â¡, ±Ô¸ð¿Í ¼ºÀå, ¼¼ºÐÈ­, Áö¿ª/±¹°¡º° ºÐ¼®, °æÀï ±¸µµ, ½ÃÀå Á¡À¯À², Æ®·»µå, Àü·«¿¡ ´ëÇØ ¼³¸íÇÕ´Ï´Ù. ½ÃÀå ½ÇÀûÀ» µû¶ó Áö¿ªº°·Î ½ÃÀå ¼ºÀåÀ» ¿¹ÃøÇÕ´Ï´Ù. ¶ÇÇÑ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå°úÀÇ ¿¬°è¿Í ´Ù¸¥ ½ÃÀå°úÀÇ ºñ±³µµ ½Ç½ÃÇß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¸ñÂ÷

Á¦3Àå ±×¸² ¸ñ·Ï

Á¦4Àå Å×ÀÌºí ¸ñ·Ï

Á¦5Àå º¸°í¼­ ±¸Á¶

Á¦6Àå ¼Ò°³¿Í ½ÃÀå Æ¯Â¡

  • ÀϹÝÀûÀÎ ½ÃÀåÀÇ Á¤ÀÇ
  • ¿ä¾à
  • ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå Á¤ÀÇ¿Í ¼¼ºÐÈ­
  • À¯Çüº° ½ÃÀå ¼¼ºÐÈ­
    • Catumaxomab (Removab¢â)
    • Blinatumomab
    • Emicizumab
    • Amivantamab
    • Faricimab
    • Teclistamab
  • ÀûÀÀÁõº° ½ÃÀå ¼¼ºÐÈ­
    • ¾Ï
    • Ç÷¿ìº´ A
    • ¾È°ú Áúȯ
  • ÃÖÁ¾ ¿ëµµº° ½ÃÀå ¼¼ºÐÈ­
    • º´¿ø
    • ¿¬±¸
    • ±âŸ ÃÖÁ¾ »ç¿ëÀÚ

Á¦7Àå ÁÖ¿ä ½ÃÀå µ¿Çâ

  • ±â¼úÀÇ Áøº¸
  • Á¦Ç° Çõ½Å
  • ÀΰøÁö´É¿¡ ÃÊÁ¡
  • Ç¥Àû¿ä¹ý ¹× º´¿ë¿ä¹ý¿¡ ´ëÇÑ ÅõÀÚ
  • Àü·«Àû ÆÄÆ®³Ê½Ê

Á¦8Àå ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¼ºÀå

  • ½ÃÀå ±Ô¸ð
  • ½ÃÀå ¼ºÀå ½ÇÀû, 2017³â-2022³â
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ¼ºÀå ¿¹Ãø, 2022³â-2027³â, 2032³â F
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ

Á¦9Àå ¼¼°è ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå ¼¼ºÐÈ­

  • ¼¼°èÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ¼¼°èÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÀûÀÀÁõº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ¼¼°èÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÃÖÁ¾ ¿ëµµº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F

Á¦10Àå ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, Áö¿ª ¹× ±¹°¡ ºÐ¼®

  • ¼¼°èÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, Áö¿ªº°, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ¼¼°èÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ±¹°¡º°, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

  • ¿ä¾à
  • ½ÃÀå °³¿ä
    • Áö¿ª Á¤º¸
    • ½ÃÀå Á¤º¸
    • ¹è°æ Á¤º¸
    • Á¤ºÎÀÇ ´ëó
    • ±ÔÄ¢
    • ±ÔÁ¦±â°ü
    • ÁÖ¿ä Çùȸ
    • ¡¼ö¼¼¾×
    • ¹ýÀμ¼ÀÇ ±¸Á¶
    • ÅõÀÚ
    • ÁÖ¿ä ±â¾÷
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ½ÇÀû, 2017-2022³â
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ¿¹Ãø, 2022-2027³â, 2032F
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÀûÀÀÁõº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÃÖÁ¾ ¿ëµµº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå : ±¹°¡º° ºÐ¼®
  • Áß±¹ ½ÃÀå
  • ¿ä¾à
  • ½ÃÀå °³¿ä
    • ±¹°¡º° Á¤º¸
    • ½ÃÀå Á¤º¸
    • ¹è°æ Á¤º¸
    • Á¤ºÎÀÇ ´ëó
    • ±ÔÄ¢
    • ±ÔÁ¦±â°ü
    • ÁÖ¿ä Çùȸ
    • ¡¼ö¼¼¾×
    • ¹ýÀμ¼ÀÇ ±¸Á¶
    • ÅõÀÚ
    • ÁÖ¿ä ±â¾÷
  • Áß±¹ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ½ÇÀû, 2017-2022³â
  • Áß±¹ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ¿¹Ãø, 2022-2027³â, 2032F
  • Áß±¹ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • Áß±¹ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÀûÀÀÁõº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • Áß±¹ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÃÖÁ¾ ¿ëµµº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • Àεµ ½ÃÀå
  • ÀεµÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ½ÇÀû, 2017-2022³â
  • ÀεµÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ¿¹Ãø, 2022-2027³â, 2032F
  • ÀεµÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ÀεµÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÀûÀÀÁõº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ÀεµÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÃÖÁ¾ ¿ëµµº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ÀϺ» ½ÃÀå
  • ÀϺ»ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ½ÇÀû, 2017-2022³â
  • ÀϺ»ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀåÀÇ ¼ºÀå ¿¹Ãø, 2022-2027³â, 2032F
  • ÀϺ»ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ÀϺ»ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÀûÀÀÁõº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ÀϺ»ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÃÖÁ¾ ¿ëµµº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • È£ÁÖ ½ÃÀå
  • È£ÁÖÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ½ÇÀû, 2017-2022³â
  • È£ÁÖÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ¿¹Ãø, 2022-2027³â, 2032F
  • È£ÁÖÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • È£ÁÖÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÀûÀÀÁõº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • È£ÁÖÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÃÖÁ¾ ¿ëµµº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • Àεµ³×½Ã¾Æ ½ÃÀå
  • Àεµ³×½Ã¾ÆÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ½ÇÀû, 2017-2022³â
  • Àεµ³×½Ã¾ÆÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ¿¹Ãø, 2022-2027³â, 2032F
  • Àεµ³×½Ã¾ÆÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • Àεµ³×½Ã¾ÆÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÀûÀÀÁõº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • Àεµ³×½Ã¾ÆÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÃÖÁ¾ ¿ëµµº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • Çѱ¹½ÃÀå
  • Çѱ¹ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ½ÇÀû, 2017-2022³â
  • Çѱ¹ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ¿¹Ãø, 2022-2027³â, 2032F
  • Çѱ¹ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • Çѱ¹ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÀûÀÀÁõº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • Çѱ¹ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÃÖÁ¾ ¿ëµµº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F

Á¦12Àå ¼­À¯·´ ½ÃÀå

  • ¿ä¾à
  • ½ÃÀå °³¿ä
    • Áö¿ª Á¤º¸
    • ½ÃÀå Á¤º¸
    • ¹è°æ Á¤º¸
    • Á¤ºÎÀÇ ´ëó
    • ±ÔÄ¢
    • ±ÔÁ¦±â°ü
    • ÁÖ¿ä Çùȸ
    • ¡¼ö¼¼¾×
    • ¹ýÀμ¼ÀÇ ±¸Á¶
    • ÅõÀÚ
    • ÁÖ¿ä ±â¾÷
  • ¼­À¯·´ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ½ÇÀû, 2017-2022³â
  • ¼­À¯·´ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ¿¹Ãø, 2022-2027³â, 2032F
  • ¼­À¯·´ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ¼­À¯·´ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÀûÀÀÁõº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ¼­À¯·´ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÃÖÁ¾ ¿ëµµº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ¼­À¯·´ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå : ±¹°¡º° ºÐ¼®
  • ¿µ±¹ ½ÃÀå
  • ¿µ±¹ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ½ÇÀû, 2017-2022³â
  • ¿µ±¹ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ¿¹Ãø, 2022-2027³â, 2032F
  • ¿µ±¹ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ¿µ±¹ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÀûÀÀÁõº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ¿µ±¹ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÃÖÁ¾ ¿ëµµº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • µ¶ÀÏ ½ÃÀå
  • µ¶ÀÏÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ½ÇÀû, 2017-2022³â
  • µ¶ÀÏ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ¿¹Ãø, 2022-2027³â, 2032F
  • µ¶ÀÏÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • µ¶ÀÏÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÀûÀÀÁõº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • µ¶ÀÏÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÃÖÁ¾ ¿ëµµº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ÇÁ¶û½º ½ÃÀå
  • ÇÁ¶û½ºÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ½ÇÀû, 2017-2022³â
  • ÇÁ¶û½º ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ¿¹Ãø, 2022-2027³â, 2032F
  • ÇÁ¶û½º ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ÇÁ¶û½º ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÀûÀÀÁõº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ÇÁ¶û½ºÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÃÖÁ¾ ¿ëµµº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F

Á¦13Àå µ¿À¯·´ ½ÃÀå

  • ¿ä¾à
  • ½ÃÀå °³¿ä
    • Áö¿ª Á¤º¸
    • ½ÃÀå Á¤º¸
    • ¹è°æ Á¤º¸
    • Á¤ºÎÀÇ ´ëó
    • ±ÔÄ¢
    • ±ÔÁ¦±â°ü
    • ÁÖ¿ä Çùȸ
    • ¡¼ö¼¼¾×
    • ¹ýÀμ¼ÀÇ ±¸Á¶
    • ÅõÀÚ
    • ÁÖ¿ä ±â¾÷
  • µ¿À¯·´ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ½ÇÀû, 2017-2022³â
  • µ¿À¯·´ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ¿¹Ãø, 2022-2027³â, 2032F
  • µ¿À¯·´ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • µ¿À¯·´ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÀûÀÀÁõº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • µ¿À¯·´ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÃÖÁ¾ ¿ëµµº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • µ¿À¯·´ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå : ±¹°¡º° ºÐ¼®
  • ·¯½Ã¾Æ ½ÃÀå
  • ·¯½Ã¾ÆÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ½ÇÀû, 2017-2022³â
  • ·¯½Ã¾ÆÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ¿¹Ãø, 2022-2027³â, 2032F
  • ·¯½Ã¾ÆÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ·¯½Ã¾ÆÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÀûÀÀÁõº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ·¯½Ã¾ÆÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÃÖÁ¾ ¿ëµµº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F

Á¦14Àå ºÏ¹Ì ½ÃÀå

  • ¿ä¾à
  • ½ÃÀå °³¿ä
    • Áö¿ª Á¤º¸
    • ½ÃÀå Á¤º¸
    • ¹è°æ Á¤º¸
    • Á¤ºÎÀÇ ´ëó
    • ±ÔÄ¢
    • ±ÔÁ¦±â°ü
    • ÁÖ¿ä Çùȸ
    • ¡¼ö¼¼¾×
    • ¹ýÀμ¼ÀÇ ±¸Á¶
    • ÅõÀÚ
    • ÁÖ¿ä ±â¾÷
  • ºÏ¹ÌÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ½ÇÀû, 2017-2022³â
  • ºÏ¹Ì ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ¿¹Ãø, 2022-2027³â, 2032F
  • ºÏ¹ÌÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ºÏ¹Ì ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÀûÀÀÁõº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ºÏ¹ÌÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÃÖÁ¾ ¿ëµµº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ºÏ¹ÌÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå : ±¹°¡º° ºÐ¼®
  • ¹Ì±¹ ½ÃÀå
  • ¿ä¾à
  • ½ÃÀå °³¿ä
    • ±¹°¡º° Á¤º¸
    • ½ÃÀå Á¤º¸
    • ¹è°æ Á¤º¸
    • Á¤ºÎÀÇ ´ëó
    • ±ÔÄ¢
    • ±ÔÁ¦±â°ü
    • ÁÖ¿ä Çùȸ
    • ¡¼ö¼¼¾×
    • ¹ýÀμ¼ÀÇ ±¸Á¶
    • ÅõÀÚ
    • ÁÖ¿ä ±â¾÷
  • ¹Ì±¹ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ½ÇÀû, 2017-2022³â
  • ¹Ì±¹ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ¿¹Ãø, 2022-2027³â, 2032F
  • ¹Ì±¹ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ¹Ì±¹ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÀûÀÀÁõº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ¹Ì±¹ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÃÖÁ¾ ¿ëµµº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F

Á¦15Àå ³²¹Ì ½ÃÀå

  • ¿ä¾à
  • ½ÃÀå °³¿ä
    • Áö¿ª Á¤º¸
    • ½ÃÀå Á¤º¸
    • ¹è°æ Á¤º¸
    • Á¤ºÎÀÇ ´ëó
    • ±ÔÄ¢
    • ±ÔÁ¦±â°ü
    • ÁÖ¿ä Çùȸ
    • ¡¼ö¼¼¾×
    • ¹ýÀμ¼ÀÇ ±¸Á¶
    • ÅõÀÚ
    • ÁÖ¿ä ±â¾÷
  • ³²¹ÌÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ½ÇÀû, 2017-2022³â
  • ³²¹ÌÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ¿¹Ãø, 2022-2027³â, 2032F
  • ³²¹ÌÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ³²¹ÌÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÀûÀÀÁõº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ³²¹ÌÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÃÖÁ¾ ¿ëµµº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ³²¹ÌÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå : ±¹°¡º° ºÐ¼®
  • ºê¶óÁú ½ÃÀå
  • ºê¶óÁúÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ½ÇÀû, 2017-2022³â
  • ºê¶óÁúÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ¿¹Ãø, 2022-2027³â, 2032F
  • ºê¶óÁúÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ºê¶óÁú ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÀûÀÀÁõº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ºê¶óÁúÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÃÖÁ¾ ¿ëµµº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F

Á¦16Àå Áßµ¿ ½ÃÀå

  • ¿ä¾à
  • ½ÃÀå °³¿ä
    • Áö¿ª Á¤º¸
    • ½ÃÀå Á¤º¸
    • ¹è°æ Á¤º¸
    • Á¤ºÎÀÇ ´ëó
    • ±ÔÄ¢
    • ±ÔÁ¦±â°ü
    • ÁÖ¿ä Çùȸ
    • ¡¼ö¼¼¾×
    • ¹ýÀμ¼ÀÇ ±¸Á¶
    • ÅõÀÚ
    • ÁÖ¿ä ±â¾÷
  • Áßµ¿ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ½ÇÀû, 2017-2022³â
  • Áßµ¿ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ¿¹Ãø, 2022-2027³â, 2032F
  • Áßµ¿ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • Áßµ¿ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÀûÀÀÁõº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • Áßµ¿ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÃÖÁ¾ ¿ëµµº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F

Á¦17Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

  • ¿ä¾à
  • ½ÃÀå °³¿ä
    • Áö¿ª Á¤º¸
    • ½ÃÀå Á¤º¸
    • ¹è°æ Á¤º¸
    • Á¤ºÎÀÇ ´ëó
    • ±ÔÄ¢
    • ±ÔÁ¦±â°ü
    • ÁÖ¿ä Çùȸ
    • ¡¼ö¼¼¾×
    • ¹ýÀμ¼ÀÇ ±¸Á¶
    • ÅõÀÚ
    • ÁÖ¿ä ±â¾÷
  • ¾ÆÇÁ¸®Ä«ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ½ÇÀû, 2017-2022³â
  • ¾ÆÇÁ¸®Ä«ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ½ÃÀå ¼ºÀå ¿¹Ãø, 2022-2027³â, 2032F
  • ¾ÆÇÁ¸®Ä«ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, À¯Çüº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ¾ÆÇÁ¸®Ä«ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÀûÀÀÁõº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F
  • ¾ÆÇÁ¸®Ä«ÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, ÃÖÁ¾ ¿ëµµº° ¼¼ºÐÈ­, ½ÇÀû°ú ¿¹Ãø, 2017-2022³â, 2027F, 2032F

Á¦18Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦19Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • F. Hoffmann-La Roche AG
    • ±â¾÷ °³¿ä
    • Á¦Ç° ¹× ¼­ºñ½º
    • »ç¾÷ Àü·«
    • À繫 °³¿ä
  • Amgen Inc
    • ±â¾÷ °³¿ä
    • Á¦Ç° ¹× ¼­ºñ½º
    • »ç¾÷ Àü·«
    • À繫 °³¿ä
  • Johnson &Johnson
    • ±â¾÷ °³¿ä
    • Á¦Ç° ¹× ¼­ºñ½º
    • »ç¾÷ Àü·«
    • À繫 °³¿ä

Á¦20Àå ÁÖ¿ä ÇÕº´°ú Àμö

  • invoX Pharma Acquired F-Star Therapeutics, Inc.
  • Amgen Acquired TeneoBio
  • Sanofi Acquired Kymab Group Ltd.
  • AbCellera Acquired OrthoMab Bispecific Platform
  • True North Acquired Stake In Biocon Biologics

Á¦21Àå ±âȸ¿Í Àü·«

  • 2027³â ¼¼°èÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå - °¡Àå »õ·Î¿î ±âȸ¸¦ Á¦°øÇÏ´Â ±¹°¡
  • 2027³â ¼¼°èÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå - ´ëºÎºÐÀÇ »õ·Î¿î ±âȸ¸¦ Á¦°øÇÏ´Â ºÎ¹®
  • 2027³â ¼¼°èÀÇ ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå - ¼ºÀå Àü·«
    • ½ÃÀå µ¿Çâ¿¡ ±âÃÊÇÑ Àü·«
    • °æÀï Àü·«

Á¦22Àå ÀÌÁ߯¯À̼º ´ÜŬ·ÐÇ×ü ½ÃÀå, °á·Ð ¹× Á¦¾È

  • °á·Ð
  • Ãßõ »çÇ×
    • Á¦Ç°
    • Àå¼Ò
    • °¡°Ý
    • ÇÁ·Î¸ð¼Ç
    • »ç¶÷µé

Á¦23Àå ºÎ·Ï

LSH 23.05.04

“BiSpecific mAbS Global Market Opportunities And Strategies To 2032 ” from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global bi-specific mAbS market as it emerges from the COVID-19 shut down.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis

Where is the largest and fastest-growing market for bi-specific mAbS? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? “The bi-specific mAbS market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider bi-specific mAbS market; and compares it with other markets.

The report covers the following chapters:

Introduction and Market Characteristics

Brief introduction to the segmentations covered in the market, definitions, and explanations about the bi-specific mAbs market.

Key Trends

Highlights the major trends shaping the global bi-specific mAbs market. This section also highlights likely future developments in the market.

Global Market Size and Growth

Global historic (2017-2022) and forecast (2022-2027), and (2027-2032) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.

Regional Analysis

Historic (2017-2022) and forecast (2022-2027), and (2027-2032) market values and growth and market share comparison by region.

Market Segmentation

Contains the market values (2017-2032) and analysis for each segment by type, by indication and by end use in the market.

Regional Market Size and Growth

Regional market size (2022), historic (2017-2022) and forecast (2022-2027), and (2027-2032) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.

Competitive Landscape

Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.

Key Mergers and Acquisitions

Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.

Market Opportunities And Strategies

This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.

Conclusions And Recommendations

This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for bi-specific mAbS providers in terms of product/service offerings, geographic expansion, marketing strategies and target groups.

Appendix

This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Scope

Markets Covered:

  • 1) By Type: Catumaxomab (Removab™); Blinatumomab; Emicizumab; Amivantamab; Faricimab; Teclistamab
  • 2) By Indication: Cancer; Hemophilia A; Ophthalmic
  • 3) By End Use: Hospitals; Research Institutes; Other End-Users
  • Companies Mentioned: F. Hoffmann-La Roche AG; Amgen Inc; Johnson & Johnson
  • Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time-series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; bi-specific mAbS indicators comparison.
  • Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1. Executive Summary

2. Table Of Contents

3. List Of Figures

4. List Of Tables

5. Report Structure

6. Introduction and Market Characteristics

  • 6.1. General Market Definition
  • 6.2. Summary
  • 6.3. BiSpecific mAbs Market Definition and Segmentations
  • 6.4. Market Segmentation By Type
    • 6.4.1. Catumaxomab (Removab™)
    • 6.4.2. Blinatumomab
    • 6.4.3. Emicizumab
    • 6.4.4. Amivantamab
    • 6.4.5. Faricimab
    • 6.4.6. Teclistamab
  • 6.5. Market Segmentation By Indication
    • 6.5.1. Cancer
    • 6.5.2. Haemophilia A
    • 6.5.3. Ophthalmic
  • 6.6. Market Segmentation By End Use
    • 6.6.1. Hospitals
    • 6.6.2. Research Institutes
    • 6.6.3. Other End-Users

7. Major Market Trends

  • 7.1. Technological Advancements
  • 7.2. Product Innovation
  • 7.3. Focus On Artificial Intelligence
  • 7.4. Investment in Targeted and Combination Therapy
  • 7.5. Strategic Partnerships

8. Global Market Size and Growth

  • 8.1. Market Size
  • 8.2. Historic Market Growth, 2017 - 2022, Value ($ Million)
    • 8.2.1. Market Drivers 2017 - 2022
    • 8.2.2. Market Restraints 2017 - 2022
  • 8.3. Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
    • 8.3.1. Market Drivers 2022 - 2027
    • 8.3.2. Market Restraints 2022 - 2027

9. Global BiSpecific mAbS Market Segmentation

  • 9.1. Global BiSpecific mAbS Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 9.2. Global BiSpecific mAbS Market, Segmentation By Indication, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 9.3. Global BiSpecific mAbS Market, Segmentation By End Use, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)

10. BiSpecific mAbS Market, Regional and Country Analysis

  • 10.1. Global BiSpecific mAbS Market, By Region, Historic and Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 10.2. Global BiSpecific mAbS Market, By Country, Historic and Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)

11. Asia-Pacific Market

  • 11.1. Summary
  • 11.2. Market Overview
    • 11.2.1. Region Information
    • 11.2.2. Market Information
    • 11.2.3. Background Information
    • 11.2.4. Government Initiatives
    • 11.2.5. Regulations
    • 11.2.6. Regulatory Bodies
    • 11.2.7. Major Associations
    • 11.2.8. Taxes levied
    • 11.2.9. Corporate Tax Structure
    • 11.2.10. Investments
    • 11.2.11. Major Companies
  • 11.3. Asia-Pacific BiSpecific mAbS Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
  • 11.4. Asia-Pacific BiSpecific mAbS Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
  • 11.5. Asia-Pacific BiSpecific mAbS Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 11.6. Asia-Pacific BiSpecific mAbS Market, Segmentation By Indication, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 11.7. Asia-Pacific BiSpecific mAbS Market, Segmentation By End Use, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 11.8. Asia-Pacific BiSpecific mAbS Market: Country Analysis
  • 11.9. China Market
  • 11.10. Summary
  • 11.11. Market Overview
    • 11.11.1. Country Information
    • 11.11.2. Market Information
    • 11.11.3. Background Information
    • 11.11.4. Government Initiatives
    • 11.11.5. Regulations
    • 11.11.6. Regulatory Bodies
    • 11.11.7. Major Associations
    • 11.11.8. Taxes levied
    • 11.11.9. Corporate tax structure
    • 11.11.10. Investments
    • 11.11.11. Major Companies
  • 11.12. China BiSpecific mAbS Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
  • 11.13. China BiSpecific mAbS Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
  • 11.14. China BiSpecific mAbS Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 11.15. China BiSpecific mAbS Market, Segmentation By Indication, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 11.16. China BiSpecific mAbS Market, Segmentation By End Use, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 11.17. India Market
  • 11.18. India BiSpecific mAbS Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
  • 11.19. India BiSpecific mAbS Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
  • 11.20. India BiSpecific mAbS Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 11.21. India BiSpecific mAbS Market, Segmentation By Indication, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 11.22. India BiSpecific mAbS Market, Segmentation By End Use, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 11.23. Japan Market
  • 11.24. Japan BiSpecific mAbs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
  • 11.25. Japan BiSpecific mAbs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
  • 11.26. Japan BiSpecific mAbs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 11.27. Japan BiSpecific mAbs Market, Segmentation By Indication, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 11.28. Japan BiSpecific mAbs Market, Segmentation By End Use, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 11.29. Australia Market
  • 11.30. Australia BiSpecific mAbs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
  • 11.31. Australia BiSpecific mAbs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
  • 11.32. Australia BiSpecific mAbs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 11.33. Australia BiSpecific mAbs Market, Segmentation By Indication, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 11.34. Australia BiSpecific mAbs Market, Segmentation By End Use, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 11.35. Indonesia Market
  • 11.36. Indonesia BiSpecific mAbs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
  • 11.37. Indonesia BiSpecific mAbs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
  • 11.38. Indonesia BiSpecific mAbs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 11.39. Indonesia BiSpecific mAbs Market, Segmentation By Indication, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 11.40. Indonesia BiSpecific mAbs Market, Segmentation By End Use, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 11.41. South Korea Market
  • 11.42. South Korea BiSpecific mAbs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
  • 11.43. South Korea BiSpecific mAbs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
  • 11.44. South Korea BiSpecific mAbs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 11.45. South Korea BiSpecific mAbs Market, Segmentation By Indication, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 11.46. South Korea BiSpecific mAbs Market, Segmentation By End Use, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)

12. Western Europe Market

  • 12.1. Summary
  • 12.2. Market Overview
    • 12.2.1. Region Information
    • 12.2.2. Market Information
    • 12.2.3. Background Information
    • 12.2.4. Government Initiatives
    • 12.2.5. Regulations
    • 12.2.6. Regulatory Bodies
    • 12.2.7. Major Associations
    • 12.2.8. Taxes levied
    • 12.2.9. Corporate tax structure
    • 12.2.10. Investments
    • 12.2.11. Major Companies
  • 12.3. Western Europe BiSpecific mAbS Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
  • 12.4. Western Europe BiSpecific mAbS Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
  • 12.5. Western Europe BiSpecific mAbS Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 12.6. Western Europe BiSpecific mAbS Market, Segmentation By Indication, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 12.7. Western Europe BiSpecific mAbS Market, Segmentation By End Use, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 12.8. Western Europe BiSpecific mAbS Market: Country Analysis
  • 12.9. UK Market
  • 12.10. UK BiSpecific mAbS Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
  • 12.11. UK BiSpecific mAbS Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
  • 12.12. UK BiSpecific mAbS Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 12.13. UK BiSpecific mAbS Market, Segmentation By Indication, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 12.14. UK BiSpecific mAbS Market, Segmentation By End Use, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 12.15. Germany Market
  • 12.16. Germany BiSpecific mAbS Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
  • 12.17. Germany BiSpecific mAbS Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
  • 12.18. Germany BiSpecific mAbS Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 12.19. Germany BiSpecific mAbS Market, Segmentation By Indication, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 12.20. Germany BiSpecific mAbS Market, Segmentation By End Use, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 12.21. France Market
  • 12.22. France BiSpecific mAbS Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
  • 12.23. France BiSpecific mAbS Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
  • 12.24. France BiSpecific mAbS Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 12.25. France BiSpecific mAbS Market, Segmentation By Indication, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 12.26. France BiSpecific mAbS Market, Segmentation By End Use, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)

13. Eastern Europe Market

  • 13.1. Summary
  • 13.2. Market Overview
    • 13.2.1. Region Information
    • 13.2.2. Market Information
    • 13.2.3. Background Information
    • 13.2.4. Government Initiatives
    • 13.2.5. Regulations
    • 13.2.6. Regulatory Bodies
    • 13.2.7. Major Associations
    • 13.2.8. Taxes Levied
    • 13.2.9. Corporate Tax Structure
    • 13.2.10. Investments
    • 13.2.11. Major Companies
  • 13.3. Eastern Europe BiSpecific mAbS Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
  • 13.4. Eastern Europe BiSpecific mAbS Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
  • 13.5. Eastern Europe BiSpecific mAbS Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 13.6. Eastern Europe BiSpecific mAbS Market, Segmentation By Indication, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 13.7. Eastern Europe BiSpecific mAbS Market, Segmentation By End Use, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 13.8. Eastern Europe BiSpecific mAbS Market: Country Analysis
  • 13.9. Russia Market
  • 13.10. Russia BiSpecific mAbS Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
  • 13.11. Russia BiSpecific mAbS Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
  • 13.12. Russia BiSpecific mAbS Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 13.13. Russia BiSpecific mAbS Market, Segmentation By Indication, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 13.14. Russia BiSpecific mAbS Market, Segmentation By End Use, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)

14. North America Market

  • 14.1. Summary
  • 14.2. Market Overview
    • 14.2.1. Region Information
    • 14.2.2. Market Information
    • 14.2.3. Background Information
    • 14.2.4. Government Initiatives
    • 14.2.5. Regulations
    • 14.2.6. Regulatory Bodies
    • 14.2.7. Major Associations
    • 14.2.8. Taxes Levied
    • 14.2.9. Corporate Tax Structure
    • 14.2.10. Investments
    • 14.2.11. Major Companies
  • 14.3. North America BiSpecific mAbS Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
  • 14.4. North America BiSpecific mAbS Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
  • 14.5. North America BiSpecific mAbS Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 14.6. North America BiSpecific mAbS Market, Segmentation By Indication, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 14.7. North America BiSpecific mAbS Market, Segmentation By End Use, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 14.8. North America BiSpecific mAbS Market: Country Analysis
  • 14.9. USA Market
  • 14.10. Summary
  • 14.11. Market Overview
    • 14.11.1. Country Information
    • 14.11.2. Market Information
    • 14.11.3. Background Information
    • 14.11.4. Government Initiatives
    • 14.11.5. Regulations
    • 14.11.6. Regulatory Bodies
    • 14.11.7. Major Associations
    • 14.11.8. Taxes Levied
    • 14.11.9. Corporate Tax Structure
    • 14.11.10. Investments
    • 14.11.11. Major Companies
  • 14.12. USA BiSpecific mAbS Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
  • 14.13. USA BiSpecific mAbS Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
  • 14.14. USA BiSpecific mAbS Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 14.15. USA BiSpecific mAbS Market, Segmentation By Indication, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 14.16. USA BiSpecific mAbS Market, Segmentation By End Use, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)

15. South America Market

  • 15.1. Summary
  • 15.2. Market Overview
    • 15.2.1. Region Information
    • 15.2.2. Market Information
    • 15.2.3. Background Information
    • 15.2.4. Government Initiatives
    • 15.2.5. Regulations
    • 15.2.6. Regulatory Bodies
    • 15.2.7. Major Associations
    • 15.2.8. Taxes Levied
    • 15.2.9. Corporate Tax Structure
    • 15.2.10. Investments
    • 15.2.11. Major Companies
  • 15.3. South America BiSpecific mAbS Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
  • 15.4. South America BiSpecific mAbs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
  • 15.5. South America BiSpecific mAbs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 15.6. South America BiSpecific mAbs Market, Segmentation By Indication, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 15.7. South America BiSpecific mAbs Market, Segmentation By End Use, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 15.8. South America BiSpecific mAbs Market: Country Analysis
  • 15.9. Brazil Market
  • 15.10. Brazil BiSpecific mAbs Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
  • 15.11. Brazil BiSpecific mAbs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
  • 15.12. Brazil BiSpecific mAbs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 15.13. Brazil BiSpecific mAbs Market, Segmentation By Indication, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 15.14. Brazil BiSpecific mAbs Market, Segmentation By End Use, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)

16. Middle East Market

  • 16.1. Summary
  • 16.2. Market Overview
    • 16.2.1. Region Information
    • 16.2.2. Market Information
    • 16.2.3. Background Information
    • 16.2.4. Government Initiatives
    • 16.2.5. Regulations
    • 16.2.6. Regulatory Bodies
    • 16.2.7. Major Associations
    • 16.2.8. Taxes Levied
    • 16.2.9. Corporate Tax Structure
    • 16.2.10. Investments
    • 16.2.11. Major Companies
  • 16.3. Middle East BiSpecific mAbS Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
  • 16.4. Middle East BiSpecific mAbs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
  • 16.5. Middle East BiSpecific mAbs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 16.6. Middle East BiSpecific mAbs Market, Segmentation By Indication, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 16.7. Middle East BiSpecific mAbs Market, Segmentation By End Use, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)

17. Africa Market

  • 17.1. Summary
  • 17.2. Market Overview
    • 17.2.1. Region Information
    • 17.2.2. Market Information
    • 17.2.3. Background Information
    • 17.2.4. Government Initiatives
    • 17.2.5. Regulations
    • 17.2.6. Regulatory Bodies
    • 17.2.7. Major Associations
    • 17.2.8. Taxes Levied
    • 17.2.9. Corporate Tax Structure
    • 17.2.10. Investments
    • 17.2.11. Major Companies
  • 17.3. Africa BiSpecific mAbS Market, Historic Market Growth, 2017 - 2022, Value ($ Million)
  • 17.4. Africa BiSpecific mAbs Market, Forecast Market Growth, 2022 - 2027, 2032F Value ($ Million)
  • 17.5. Africa BiSpecific mAbs Market, Segmentation By Type, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 17.6. Africa BiSpecific mAbs Market, Segmentation By Indication, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)
  • 17.7. Africa BiSpecific mAbs Market, Segmentation By End Use, Historic And Forecast, 2017 - 2022, 2027F, 2032F, Value ($ Million)

18. Competitive Landscape and Company Profiles

19. Company Profiles

  • 19.1. F. Hoffmann-La Roche AG
    • 19.1.1. Company Overview
    • 19.1.2. Products And Services
    • 19.1.3. Business Strategy
    • 19.1.4. Financial Overview
  • 19.2. Amgen Inc
    • 19.2.1. Company Overview
    • 19.2.2. Products And Services
    • 19.2.3. Business Strategy
    • 19.2.4. Financial Overview
  • 19.3. Johnson & Johnson
    • 19.3.1. Company Overview
    • 19.3.2. Products And Services
    • 19.3.3. Business Strategy
    • 19.3.4. Financial Overview

20. Key Mergers and Acquisitions

  • 20.1. invoX Pharma Acquired F-Star Therapeutics, Inc.
  • 20.2. Amgen Acquired TeneoBio
  • 20.3. Sanofi Acquired Kymab Group Ltd.
  • 20.4. AbCellera Acquired OrthoMab Bispecific Platform
  • 20.5. True North Acquired Stake In Biocon Biologics

21. Opportunities And Strategies

  • 21.1. Global BiSpecific mAbS Market In 2027 - Countries Offering Most New Opportunities
  • 21.2. Global BiSpecific mAbS Market In 2027 - Segments Offering Most New Opportunities
  • 21.3. Global BiSpecific mAbS Market In 2027 - Growth Strategies
    • 21.3.1. Market Trend Based Strategies
    • 21.3.2. Competitor Strategies

22. Bi-Specific mAbs Market, Conclusions And Recommendations

  • 22.1. Conclusions
  • 22.2. Recommendations
    • 22.2.1. Product
    • 22.2.2. Place
    • 22.2.3. Price
    • 22.2.4. Promotion
    • 22.2.5. People

23. Appendix

  • 23.1. Market Data Sources
  • 23.2. Research Methodology
  • 23.3. Currencies
  • 23.4. The Business Research Company
  • 23.5. Copyright and Disclaimer
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦